title: Maleylated-BSA suppresses IFN-gamma-mediated Ia expression in murine peritoneal macrophages.
abstract: Maleylated bovine serum albumin (maleyl-BSA) and other polyanionic polymers that are recognized by cell surface receptors on macrophages have been shown to induce chemotaxis, protease secretion, and tumoricidal function in this cell type. In this paper the effect of maleyl-BSA on Ia antigen expression has been evaluated. In a fashion similar to LPS, maleyl-BSA suppressed IFN-gamma-induced expression of Ia in a time- and dose-dependent manner. Also like LPS, maleyl-BSA stimulated the production and secretion of substantial amounts of PGE2 over a 24-hr period. This did not, however, appear to be the primary mechanism by which expression of Ia was suppressed, because co-treatment of the cells with indomethacin, which totally inhibited the production of PGE2, only minimally affected the suppressive activity. Surprisingly, the suppressive activity of both maleyl-BSA and LPS could be largely abrogated by co-treatment of the cells with cyclohexamide during the time period when Ia expression was sensitive to suppression. This effect was selective in that PGE2- or dibutyryl cyclic AMP-induced suppression of Ia expression was not affected by cyclohexamide treatment. The data support the concept that there are multiple molecular mechanisms involved in the negative regulation of IFN-gamma-induced Ia expression in macrophages. Such mechanisms may include, in addition to the synthesis of PGE2 and consequent elevation in intracellular levels of cyclic AMP, one or more proteins made early after treatment with either maleyl-BSA or LPS. Thus the function of some of these early gene products may be to regulate expression of functional genes such as that encoding Ia antigen.
mesh_terms: D000418:Albumins / Q000494:pharmacology*; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D003864:Depression, Chemical; D015232:Dinoprostone; D005786:Gene Expression Regulation / Q000187:drug effects*; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis* / Q000235:genetics; D007213:Indomethacin / Q000494:pharmacology; D007371:Interferon-gamma / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL / Q000276:immunology; D010529:Peritoneal Cavity / Q000166:cytology; D011458:Prostaglandins E / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000494:pharmacology; D012710:Serum Albumin, Bovine
chemical_list: D000418:Albumins; D000949:Histocompatibility Antigens Class II; D008070:Lipopolysaccharides; D011458:Prostaglandins E; D011994:Recombinant Proteins; C049877:maleylalbumin; D012710:Serum Albumin, Bovine; D003994:Bucladesine; D007371:Interferon-gamma; D003513:Cycloheximide; D015232:Dinoprostone; D007213:Indomethacin